Henry Schein, Inc. (NASDAQ:HSIC) Stock Has Average Target Price of $93.57

Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $93.86.

A number of research analysts have issued reports on HSIC shares. Morgan Stanley boosted their price target on Henry Schein from $64.00 to $68.00 and gave the stock an “underweight” rating in a research report on Tuesday. Barrington Research set a $104.00 price target on Henry Schein in a research note on Wednesday, August 5th. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. BTIG Research lifted their price objective on shares of Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Finally, Leerink Partners set a $92.00 price objective on shares of Henry Schein and gave the company a “market perform” rating in a research note on Wednesday, October 14th.

View Our Latest Stock Report on Henry Schein

Henry Schein Stock Performance

HSIC opened at $84.80 on Tuesday. The company has a current ratio of 1.33, a quick ratio of 0.76 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $85.60 and its 200-day moving average is $81.73. The stock has a market cap of $9.37 billion, a PE ratio of 23.23, a price-to-earnings-growth ratio of 1.60 and a beta of 0.87. Henry Schein has a twelve month low of $68.70 and a twelve month high of $92.18.

Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.20. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the company posted $1.38 EPS. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, analysts predict that Henry Schein will post 5.45 earnings per share for the current year.

Institutional Trading of Henry Schein

Institutional investors have recently made changes to their positions in the stock. Southpoint Capital Advisors LP raised its stake in shares of Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after buying an additional 700,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Henry Schein by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after buying an additional 56,687 shares during the period. M.D. Sass LLC lifted its holdings in shares of Henry Schein by 2.9% in the first quarter. M.D. Sass LLC now owns 1,273,316 shares of the company’s stock valued at $93,843,000 after buying an additional 35,443 shares during the period. Bank of America Corp DE boosted its stake in Henry Schein by 5.9% during the first quarter. Bank of America Corp DE now owns 1,221,585 shares of the company’s stock valued at $90,031,000 after buying an additional 68,593 shares in the last quarter. Finally, Defilade Capital Management L.P. boosted its stake in Henry Schein by 94.8% during the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock valued at $45,992,000 after buying an additional 303,615 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

(Get Free Report)

Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.

Further Reading

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.